A phase II trial of TAS-102 in patients with colorectal cancer with ctDNA-defined minimal residual disease post-adjuvant therapy compared to synthetic control cohort: Results from the MD Anderson INTERCEPT program.
Year: 2024
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Andrew Jared Pellatt, Giulia Maddalena, Alisha Heather Bent, Christine Megerdichian Parseghian, Ryan W Huey, Kanwal Pratap Singh Raghav, Van K. Morris, Michael J. Overman, Maria Pia Morelli, Jason Willis, Phat Le, John Paul Y.C. Shen, Kristin Alfaro, Kathryn Aziz, Robert J. Kell, Ryan Sun, Scott Kopetz, Arvind Dasari
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Taiho Pharmaceutical
OpenAlex ID: W4399328091